These studies and others suggest α6β4 targeted therapy could have broad implications for cancer therapy, particularly in combination with other targeted agents in biological pathways, such as EGFR inhibitors, HerceptinTM (targeting ErbB2), or AvastinTM (targeting Vascular endothelial growth factor). Here, EGFR is linked to cancer.